Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
US5405837A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | May 18, 1993 |
| Grant date | Apr 11, 1995 |
| Priority date | — |
| Expiry date | May 18, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the treatment of neoplastic disease in warm blooded animals using the sequential administration of tiazofurin and ribavirin. Tiazofurin is administered first in a high dose in order to facilitate a sharp decrease in IMP DH activity. These gains are consolidated by the continual administration of tiazofurin until the hematological levels have stabilized and remission is achieved. Once the patient is in remission, ribavirin is administered in steadily tapering dosages until the minimum dosage that will retain the beneficial effect of the tiazofurin is achieved. The IMP DH activity, GTP concentration, and hematological data is continually monitored throughout the treatment and dosages adjusted.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.